多发性硬化自体造血干细胞移植:NMSS建议
美国国家多发性硬化协会医学咨询委员会综述近期文献,提出自体造血干细胞移植(AHSCT)用于复发型多发性硬化的推荐。AHSCT在复发型患者中显示高疗效和持久效果,安全性较前改善;推荐用于高效疾病修正治疗下仍有突破疾病活动或存在禁忌者,最佳候选为小于50岁、病程小于10年者,并应在有经验中心进行。
要点
- AHSCT可用于高效DMT治疗下仍有突破疾病活动或存在禁忌的复发型多发性硬化患者。
- 最佳候选可能为年龄小于50岁且病程小于10年的患者。
- 该操作应在具有丰富经验和专业知识的中心进行。
核心结论
- AHSCT可能对高效疾病修正治疗下仍有突破疾病活动或存在禁忌的复发型多发性硬化患者是有用的治疗选择。
研究设计与样本
- 美国国家多发性硬化协会医学咨询委员会综述近期文献并提出建议。
主要发现
- AHSCT研究反复显示在复发型多发性硬化患者中具有高疗效和持久结果。
- 近期研究显示该操作安全性显著改善,死亡率较早期报告大幅降低。
- 关于最佳候选者特征正逐渐形成共识。
关键数值与推荐
- 最佳候选可能为年龄小于50岁且病程小于10年的患者。
- 推荐用于高效疾病修正治疗下仍有突破疾病活动或存在高效疾病修正治疗禁忌者。
临床怎么用
- 该操作应在具有丰富经验和专业知识的中心进行。
- 理想情况下,接受该操作者应录入单一数据库。
局限性
- 理想方案尤其是最佳免疫清除预处理方案仍存疑问。
- 需要更大规模随机临床试验明确AHSCT是否优于当前最有效疾病修正药物,相关试验(BEAT-MS)正在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Autologous hematopoietic stem cell transplant (AHSCT) for multiple sclerosis has gained increasing interest in recent years. Despite the availability of many US Food and Drug Administration-approved disease-modifying therapies, some patients do not respond adequately and others may have very early aggressive disease that prompts consideration of alternative, highly effective, long-lasting therapy. The National Medical Advisory Committee of the National Multiple Sclerosis Society has reviewed recent literature on AHSCT for the purpose of making recommendations about its use based on current knowledge, as well as pointing out areas of controversy and issues requiring further research. OBSERVATIONS: Studies on AHSCT have repeatedly demonstrated high efficacy and a durable outcome in people with relapsing multiple sclerosis. Recent studies have shown considerable improvement in the safety of the procedure, with much lower mortality rates than were reported earlier. Consensus is emerging about the characteristics of the best candidates for the procedure. Questions remain about the ideal protocol, particularly about the best conditioning regimen to be used to kill immune cells. Larger randomized clinical trials are needed to address the question of whether AHSCT has advantages over the most efficacious disease-modifying agents currently available. One such trial (Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis [BEAT-MS) is currently in progress. CONCLUSIONS AND RELEVANCE: The National Multiple Sclerosis Society believes that AHSCT may be a useful treatment option for people with relapsing multiple sclerosis who demonstrate substantial breakthrough disease activity (ie, new inflammatory central nervous system lesions and/or clinical relapses) despite treatment with high-efficacy disease-modifying therapy or have contraindications to high-efficacy disease-modifying therapies. The best candidates are likely people younger than 50 years with shorter durations of disease (<10 years). The procedure should only be performed at centers with substantial experience and expertise. Ideally, recipients of the procedure should be entered into a single database, and further research is needed to establish ideal cell mobilization and immune-conditioning regimens.
引用
- Miller AE, Chitnis T, Cohen BA, et al. Autologous Hematopoietic Stem Cell Transplant in Multiple Sclerosis: Recommendations of the National Multiple Sclerosis Society. JAMA Neurol. 2021. PMID: 33104165. doi:10.1001/jamaneurol.2020.4025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。